A Phase I, Open-label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetic, Efficacy and Preliminary Food Effect of BB3008 Tablet Administered Orally to Patients With Advanced Solid Tumors
Latest Information Update: 27 Nov 2023
At a glance
- Drugs BB 3008 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors BroadenBio
Most Recent Events
- 27 Nov 2023 New trial record